scholarly journals Progesterone receptors - animal models and cell signaling in breast cancer: Implications for breast cancer of inclusion of progestins in hormone replacement therapies

2002 ◽  
Vol 4 (6) ◽  
Author(s):  
Catherine Schairer
Keyword(s):  
Breast Cancer ◽  
Animal Models ◽  
Cell Signaling ◽  
Hormone Replacement ◽  
Progesterone Receptors

Outcomes of Turkish National Breast Cancer Registry.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e12517-e12517
Author(s):  
Saadettin Kilickap ◽  
Mahmut Gumus ◽  
Dogan Uncu ◽  
Metin Ozkan ◽  
Irfan Cicin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ductal Carcinoma ◽  
Hormone Replacement ◽  
Progesterone Receptors ◽  
Health Concern ◽  
Her2 Positive ◽  
Cross Sectional ◽  
National Breast ◽  
Outcome Information ◽  
Stage 4

Background: The aim of this registry was to collect demographic, diagnostic, treatment, and outcome information about Turkish patients with breast cancer (BC). Methods: It was designed as a multicenter, cross-sectional, non-interventional study conducted on new and previously diagnosed BC cases applied to 28 medical oncology outpatient clinics between 2012 and 2015. A total of 16841 male (n = 153) and female (n = 16688) patients > 18 years were included. Results: Mean age of BC patients was 52.0±11.5 years. Among women, 53.7% were postmenopausal, and 24.4% were receiving hormone replacement (HRT) and/or oral contraceptive therapies (OCT). At time of diagnosis, 18.2% of patients presented with Stage 1, 48.5% with Stage 2, 25.5% with Stage 3, and 7.9% with Stage 4 BC. In 79,8% of the patients histopathology was invasive ductal carcinoma. Estrogen (ER) and progesterone receptors (PR) were positive in 74.7%, and 69.4% of patients, respectively. Diagnostic immunohistochemistry (IHC) was performed in 90.4% of patients. HER2+ was found in 30.2% of patients. HER2+ was observed in 27.6% Stage I, 27.6% Stage II, 36.2% Stage III, and in 41.7% Stage 4 BC. ER and PR positivity were 62.4% and 56.4% among HER2+ patients, respectively. Neoadjuvant therapy was administered in 10.6% and adjuvant therapy was administered in 73.2% of patients. Between 2010 and 2015, trastuzumab was administered in 68.3% of adjuvant (n = 1959), and 7.5% of neoadjuvant (n = 215) HER2+ patients. Conclusions: BC is a major health concern. Majority of the patients are diagnosed in stage 2 or 3, therefore screening should be improved to diagnose patients at earlier stages. In HER2 positive patients, neoadjuvant trastuzumab usage is limited despite its known advantages.

scholarly journals Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer

2018 ◽  
Vol 25 (12) ◽  
pp. R605-R624 ◽  
Author(s):  
Caroline A Lamb ◽  
Victoria T Fabris ◽  
Britta M Jacobsen ◽  
Alfredo Molinolo ◽  
Claudia Lanari
Keyword(s):  
Breast Cancer ◽  
Current Knowledge ◽  
Hormone Replacement ◽  
Progesterone Receptors ◽  
Experimental Models ◽  
Breast Carcinogenesis ◽  
Breast Cancer Patients ◽  
Cognate Receptor ◽  
Estrogen Receptor Signaling ◽  
Cancer Models

There is a consensus that progestins and thus their cognate receptor molecules, the progesterone receptors (PRs), are essential in the development of the adult mammary gland and regulators of proliferation and lactation. However, a role for natural progestins in breast carcinogenesis remains poorly understood. A hint to that possible role came from studies in which the synthetic progestin medroxyprogesterone acetate was associated with an increased breast cancer risk in women under hormone replacement therapy. However, progestins have also been used for breast cancer treatment and to inhibit the growth of several experimental breast cancer models. More recently, PRs have been shown to be regulators of estrogen receptor signaling. With all this information, the question is how can we target PR, and if so, which patients may benefit from such an approach? PRs are not single unique molecules. Two main PR isoforms have been characterized, PRA and PRB, which exert different functions and the relative abundance of one isoform with respect to the other determines the response of PR agonists and antagonists. Immunohistochemistry with standard antibodies against PR do not discriminate between isoforms. In this review, we summarize the current knowledge on the expression of both PR isoforms in mammary glands, in experimental models of breast cancer and in breast cancer patients, to better understand how the PRA/PRB ratio can be exploited therapeutically to design personalized therapeutic strategies.

scholarly journals Therapeutic and chemopreventive potential of luteolin against growth and metastasis of breast cancer

2015 ◽  
Author(s):  
◽  
Matthew T. Cook
Keyword(s):  
Breast Cancer ◽  
Animal Models ◽  
Cancer Cells ◽  
Postmenopausal Women ◽  
Human Breast Cancer ◽  
Breast Cancer Cells ◽  
Hormone Replacement ◽  
The Body ◽  
Human Breast Cancer Cells ◽  
Human Breast

Breast cancer is the second leading cause of cancer-related death in older women. Many postmenopausal women undergo hormone replacement therapy (HRT) to alleviate the symptoms of menopause. Recent studies implicate the progestin component of HRT as being most likely responsible for elevated breast cancer risk and increased mortality. Using animal models and cell culture we explored the preventive and therapeutic potential of luteolin (LU), a naturally-occurring compound found commonly in fruits and vegetables, and examined its ability to both prevent the onset of breast cancer, and inhibit its growth and metastasis. LU effectively blocked progestin (P)-induced intratumoral vascularization in our animal models when given preventatively or therapeutically. LU blocked P-stimulated effects in cultured human breast cancer cells, including inhibiting the enrichment of a subpopulation of human breast cancer cells that are believed to be responsible for tumor initiation. Such cells are difficult to treat by conventional methods. Progestins not only elevate the risk of breast cancer in postmenopausal women but have also been implicated in making tumor cells metastatic, increasing their ability to spread from the breast to distant sites around the body. With this in mind we utilized a hormone-independent model of lung metastasis, since most hormone-dependent cancer cells ultimately become hormone-resistant and lose therapeutic markers. LU significantly reduced the formation of lung colonies arising from these human breast cancer cells, with little or no animal toxicity. Overall, these studies provide compelling evidence that LU possesses chemopreventive, therapeutic, and anti-metastatic properties which might be harnessed to combat breast cancer.

Hormone replacement therapy and breast cancer

1996 ◽  
Vol 5 (6) ◽  
pp. 349-350
Author(s):  
J. L. Stanford
Keyword(s):  
Breast Cancer ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement
Sign in / Sign up

Export Citation Format

Share Document